A Phase II Clinical Trial Evaluating Combination Therapy Using DCVax-L (Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen) and Nivolumab (an Anti-PD-1 Antibody) for Subjects With Recurrent Glioblastoma Multiforme
Not yet recruiting
Phase of Trial: Phase II
Latest Information Update: 18 Oct 2017
At a glance
- Drugs Dendritic cell vaccine-Northwest Biotherapeutics (Primary) ; Nivolumab (Primary)
- Indications Glioblastoma
- Focus Adverse reactions; Therapeutic Use
- 11 Oct 2017 Planned initiation date changed from 1 Oct 2017 to 1 Jan 2018.
- 17 Aug 2017 Planned End Date changed from 1 Aug 2020 to 1 Oct 2020.
- 17 Aug 2017 Planned primary completion date changed from 1 Aug 2019 to 1 Oct 2019.